We undertook a systematic review to determine the optimal dose of oxytocin after elective caesarean section or caesarean section in labouring women. We identified seven trials. These trials raise questions about the use of high dose (10 international units; IU) or moderate dose (5 IU) oxytocin in both settings and provide evidence that lower doses are equally effective but associated with significantly fewer side-effects. For elective caesarean section, a slow 0.3 to 1 IU bolus of oxytocin over one minute, followed by an infusion of 5 to 10 IU.h -1 for four hours represents an evidence-based approach to dosing for women at low risk of postpartum haemorrhage. For the labouring parturient a slow 3 IU bolus of oxytocin, followed by an infusion of 5 to 10 IU.h -1 for four hours is supported by limited evidence. These doses represent a starting point in the control of postpartum haemorrhage after caesarean section and do not reduce the need for mandatory active observation of the clinical situation, to detect situations that require additional doses of oxytocin or other uterotonic drugs. These doses of oxytocin minimise the risk of adverse haemodynamic changes as well as the unpleasant side-effect of nausea.
BACKGROUND
Oxytocin is a naturally occurring peptide hormone produced in the paraventricular nuclei of the hypothalamus and transported in secretory granules to the posterior pituitary for subsequent release. It has two main effects: uterine contraction and milk ejection from the lactating mammary gland. Oxytocin has very weak anti-diuretic hormone activity which necessitates infusion in an isotonic solution 1 . It is largely inactivated in the gastrointestinal tract, so administration is intravenous, intramuscular or transmucosal as nasal spray. Intravenous oxytocin has an onset of action of one to two minutes and a half-life of about 15 minutes 2,3 . Given intramuscularly, the onset is two to four minutes and duration of action is 30 to 60 minutes 3, 4 . Oxytocin is commonly available as a synthetic formulation (Syntocinon, Novartis Pharmaceuticals Australia Pty Ltd, North Ryde, NSW) which is identical to the peptide hormone but not contaminated with vasopressin, as was the case with the older biologically derived formulation.
Guidelines recommend the use of oxytocin to facilitate the third stage of labour and decrease the risk of postpartum haemorrhage. During the third stage of labour after vaginal delivery, active management consisting of intramuscular oxytocin 10 international units (IU) and controlled cord traction, has been shown to significantly reduce the incidence of postpartum haemorrhage 5, 6 . Good evidence supports use at caesarean section to decrease postpartum blood loss 6, 7 . However, the optimum dose is unknown. Historically a 10 IU intravenous bolus of oxytocin was given after caesarean delivery of the foetus. More recent guidelines, largely resulting from the Confidential Enquiries into Maternal Deaths 8 in the United Kingdom, recommend a 5 IU bolus, to be administered as a slow injection because of the potential for haemodynamic instability after a rapid 10 IU bolus 9 . A 2010 survey indicates that 97% of Australian and New Zealand obstetricians requested a 10 IU (66%) or 5 IU (31%) bolus to be given at elective caesarean section 10 . This survey found that obstetricians with more than 20 years of experience were more likely to ask for 10 IU. Another survey in 2010 in Great Britain and Ireland also revealed variations in practice, with greater reliance on a 5 IU bolus (requested by 85 to 95% across individual countries) 11 .
INTRODUCTION
Oxytocin, commonly used to prevent postpartum atony and haemorrhage, continues to generate controversy among anaesthetists and obstetricians caring for women having caesarean sections. We undertook a systematic review of the literature to determine the ideal dose of oxytocin at caesarean section. Medline, Embase and the Cochrane databases were searched using the terms "oxytocin and caesarean section" for English language, randomised controlled trials investigating oxytocin dose at caesarean section. At total of 1379 articles were initially found. Their titles were read, abstracts obtained if indicated by the title and the reference lists of identified papers were examined for further papers. Seven papers were identified meeting the criteria: five dealt with elective caesarean section and two with 'labouring' caesarean section. We chose this term because one study did not differentiate oxytocin-augmented from unaugmented labour and 'non-elective' is a broader descriptor that includes women not in labour. The elective and labouring studies were separated, because labour in which oxytocin is administered leads to down-regulation and decreased responsiveness of uterine oxytocin receptors 12, 13 and it was therefore expected that higher oxytocin doses would be required for these women.
CLINICAL TRIALS
The seven articles identified were heterogeneous in study design. They are presented briefly in tabular form and detailed in the text. All studies were of randomised, double-blind design except that of Carvalho et al 14 . Table 1 shows studies at elective caesarean, by publication date, and Table 2 summarises labouring caesarean section studies.
Elective caesarean delivery
In 1997, Sarna et al 15 studied the response to different doses of oxytocin: 5, 10, 15 and 20 IU injected at 1 IU/minute. As in all subsequent studies, the women were at low risk for postpartum haemorrhage and had surgery under neuraxial anaesthesia. An oxytocin infusion was begun immediately after clamping the umbilical cord and the obstetrician rated uterine tone at 5, 10, 15 and 20 minutes. There was no significant difference in uterine tone at any time point, nor any difference in estimated blood loss or postoperative haematocrit. No patient required ephedrine for hypotension but nausea, vomiting and other side-effects were not recorded. It is unclear whether uterine massage was used. Doses below 5 IU were not studied and the authors noted that all doses investigated may have been on the plateau of the dose-response curve. The slow rate of injection (1 IU/minute) may have minimised side-effects. The study conclusion was that 5 IU or more resulted in similar outcomes at elective caesarean section.
In 2004 oxytocin at elective caesarean delivery, using an up-and-down sequential allocation design, to allow estimation of the ED 90 . An initial dose of oxytocin at 0.5 IU per five seconds was started after delivery of the foetal shoulder. Cord traction but not uterine massage was applied. The obstetrician, who was blinded to oxytocin dose, rated uterine tone after three minutes. If unsatisfactory, an additional 0.5 IU oxytocin was given and in the recovery unit all patients received an oxytocin infusion at 2.4 IU.hour -1 . This study estimated the ED 90 of oxytocin to be 0.35 IU (95% confidence interval 0.18 to 0.52 IU). The most common side-effects of oxytocin were hypotension, nausea and flushing, which the authors speculated might have been related to the speed of injection of oxytocin. The updown, biased coin allocation design is an established method of determining a meaningful dose while minimising patient numbers. This was a single-blind study so bias is possible but blinded obstetricians, who may be considered conservative when assessing uterine tone, performed the rating and could request more oxytocin. The finding of a low ED 90 was surprising but appears valid for this surrogate outcome. Sartain et al 16 compared the efficacy of two doses of oxytocin, either 2 or 5 IU, at elective caesarean section. Eighty parturients received intravenous oxytocin over five to 10 seconds immediately after delivery and cord clamping, followed by an infusion at 10 IU.hour -1 for four hours. The placenta was delivered with controlled cord traction but no uterine massage was performed. The two groups were comparable for uterine tone, blood loss and use of uterotonic drugs (17% of each group). The primary outcome of the study was change in maternal heart rate rather than blood pressure, the investigators considering that it was a more sensitive indicator of haemodynamic change in the absence of invasive arterial blood pressure monitoring. The higher dose of oxytocin resulted in a significantly greater increase in heart rate (32 vs 24 beats.minute -1 ), decrease in mean arterial pressure (13 vs 6 mmHg), and more nausea and antiemetic use (32.5 vs 5%). The rapid speed of injection of oxytocin should be noted. Given that 17% of the sample required additional uterotonic drugs it can be argued that any oxytocin bolus is a starting point in the prevention of postpartum haemorrhage and that ongoing vigilance is mandatory.
George et al 17 studied the ED 90 for oxytocin infusions, without a preceding bolus, at elective caesarean section of 40 parturients. The infusion continued for one hour after delivery of the foetus and cord clamping and was then followed by a 30 IU.l -1 infusion at 150 ml.hour -1 in the recovery unit. A biased coin, up-down sequential allocation design method was used and 'manual or assisted delivery' of the placenta performed at the obstetrician's discretion. If uterine tone was rated as unsatisfactory after three minutes, uterine massage or additional uterotonic drug were permitted. The ED 90 was 0.29 IU.minute -1 (confidence interval 0.15 to 0.43 IU.minute -1 ). Continuing the infusion for an hour may have been an important factor in this study because the dose rate is higher than that of commonly used postpartum infusions with 40 IU over four hours resulting in 0.17 IU per minute.
Butwick et al 18 randomised 75 patients undergoing elective caesarean section to one of four bolus doses (0 [placebo], 0.5, 1, 3 or 5 IU), given over 15 seconds after delivery of the foetus and clamping the umbilical cord. The obstetrician manually removed the placenta, performed uterine massage, and assessed uterine tone after two minutes. One or two additional boluses of oxytocin 2.5 IU were permitted before other uterotonic drugs were used. An oxytocin infusion at 5 IU.hour -1 for two hours was started once uterine tone was considered adequate, followed by 10 IU.hour -1 for an unspecified length of time. Outcome measures were uterine tone (assessed at two, three, six and nine minutes), blood loss and maternal side-effects of oxytocin. At two minutes uterine tone was similar in all groups, with 73% of the placebo group having adequate uterine tone (66% at three minutes) -nevertheless, almost half the placebo group ultimately required rescue oxytocin. Uterine tone scores were significantly lower at two and three minutes in the placebo group compared to the 3 and 5 IU groups (P <0.05) and rescue oxytocin was only required by 20% of each of the 0.5 and 1 IU groups. None of the 3 and 5 IU group patients required extra oxytocin, which is interesting because other studies have demonstrated a requirement even after 2 or 5 IU. Uterine massage may explain this difference, because it was not used in other studies. Hypotension affected 47% of the 5 IU group patients: one woman became tachycardic (120 beats.minute -1 ) and two women complained of nausea (after 0 and 5 IU). The speed of injection may be relevant, all doses being given over 15 seconds. The estimated blood loss was similar across the groups. This study demonstrates that adequate tone may be achieved with little or no oxytocin but that some oxytocin is advisable, given that 47% of the placebo group ultimately required such treatment.
In a double-blind study Munn et al 19 compared two oxytocin infusion regimens to prevent uterine atony at caesarean delivery in labouring women. After delivery either a low dose (0.33 IU.minute -1 ) or a high dose (2.7 IU.minute -1 ) infusion of oxytocin was given for 30 minutes following uterine massage and controlled cord traction to deliver the placenta. In both groups this was followed by 20 IU.l -1 over eight hours. If deemed necessary, atony was treated by the addition of up to 20 IU oxytocin into the original infusion or the use of other uterotonic medications. Women in the low dose group required additional uterotonic agents significantly more often (39 vs 19%, P <0.001). No significant difference was observed in the incidence of hypotension or blood loss.
Balki et al 20 published another dose finding study in 30 women that determined the ED 90 of oxytocin for labour arrest. Participants had epidural analgesia, oxytocin augmentation of labour for a minimum of two hours and no predisposing conditions for uterine atony or haemorrhage. The oxytocin bolus was given with delivery of the foetal shoulder. Cord traction was applied but uterine massage was not performed. After three minutes the obstetrician rated uterine tone and could then massage the uterus or request additional doses of oxytocin 0.5 IU. All patients received an oxytocin infusion at 2.4 IU.hour -1 for up to eight hours after delivery. The ED 90 was determined to be 2.99 IU (95% confidence interval 2.32 to 3.67). The bolus was given over 30 seconds and hypotension, tachycardia, and nausea occurred post delivery.
DISCUSSION

Adverse effects
In considering the risk/benefit of prophylactic oxytocin, the anaesthetist must be aware of its adverse affects, which are hypotension, tachycardia, increased cardiac output, myocardial ischaemia, flushing, nausea, vomiting and a mild antidiuretic effect. Thomas et al 21 studied the haemodynamic effects of oxytocin 5 IU given as a fast bolus or as an infusion over five minutes at elective caesarean section. The oxytocin bolus resulted in a greater increase in heart rate (Δ beats.minute -1 : 17 vs 10) and decrease in mean arterial pressure (Δ mmHg: 27 vs 8). There was no difference in blood loss.
A randomised, double-blind study by Svanström et al 22 compared the haemodynamic effects of 1) 10 IU oxytocin over 30 seconds after elective caesarean section; 2) 0.2 mg methylergometrine after elective caesarean section; and 3) 10 IU oxytocin over 30 seconds in non-pregnant controls. In addition to arterial blood pressure, a 12-lead electrocardiogram, vectorcardiography and the spatial ST-change vector magnitude were used to identify myocardial ischaemia. Oxytocin 10 IU induced chest pain, transient tachycardia (increase up to 28 beats.minute -1 ), hypotension (decreased in mean arterial pressure from 90 to 57 mmHg), and signs of myocardial ischaemia, as indicated by electrocardiogram and ST-change vector magnitude, in both pregnant and control patients. The patients given methylergometrine had mild hypertension (mean arterial pressure increased from 91 to 102 mmHg).
A double-blind study of 74 parturients by McLeod et al 23 investigated maternal haemodynamics at elective caesarean section after a 5 IU oxytocin bolus over three minutes, followed by either a placebo or a 30 IU infusion over four hours. The placenta was delivered by controlled cord traction and uterine massage was not performed. ECG, non-invasive blood pressure and thoracic bioimpedance were assessed. There was no requirement for additional medical, surgical, or radiological intervention in any subject but both groups experienced significant haemodynamic changes. The slow bolus of oxytocin resulted in a 31% increase in cardiac index, a 25% rise in left cardiac work index, a 13% increase in heart rate and a 22% fall in systemic vascular resistance index. These parameters slowly recovered towards, but never attained, preoperative values in both active and placebo groups during the four-hour experimental period.
Luke and Brown 24 noted that between 1980 and 2004 the proportion of all births increased threefold in women aged ≥35 years and nearly fourfold in women 40 years and over. This period was accompanied by an increase in population obesity. Advancing age 25 and obesity are associated with an increased risk of ischaemic heart disease, hypertension and diabetes, mandating particular care with drugs that alter haemodynamic status, especially as oxytocin can induce chest pain 22 .
For the parturient the 'minor' side-effects of oxytocin such as nausea and vomiting are of importance too. Sartain and co-investigators 16 suggested that the observed haemodynamic changes support the use of a 2 IU dose of oxytocin (which was as effective as 5 IU) and that a lower rate of nausea is in itself sufficient reason to use 2 IU rather than 5 IU of oxytocin. 
History
Active management of the third stage of labour for vaginal delivery protocols include 10 IU oxytocin intramuscularly at delivery of the anterior shoulder and controlled cord traction. This strategy decreases postpartum haemorrhage [5] [6] [7] , which is of greatest risk in the first few hours after delivery. Given the short duration of action of intravenous oxytocin as compared to intramuscular oxytocin, when using a slow, intravenous bolus of oxytocin it should be followed by an infusion until more evidence becomes available from large multicentre studies 26 . The optimum infusion dose is unclear. One can even question whether bolus is necessary given the intriguing study of King et al 27 in which they compared uterine tone after a slow 5 IU bolus of oxytocin or normal saline followed by a 40 IU infusion over 30 minutes, then a 20 IU infusion over eight hours. They found better initial tone with the oxytocin bolus but no difference in the need for additional uterotonic drugs to prevent or treat postpartum haemorrhage. The initial infusion rate was higher than typically used but their findings warrant further investigation.
Any evaluation of the dose of oxytocin required to effectively prevent postpartum haemorrhage must take into account the specific circumstances encountered. Not only is there a significant difference between labouring women and elective caesarean section, but also the efforts of the obstetrician play an important role. Both Abdel-Aleem 28 and Butwick et al 18 comment that uterine massage and/ or cord traction must be considered as contributing or confounding factors when the effects of oxytocin are evaluated. With manual removal of the placenta and subsequent uterine massage, 53% of patients in the study by Butwick et al did not need any oxytocin.
To induce labour, oxytocin doses in the range of 1 to 6 mIU.minute - 1 29 , and not exceeding 20 mIU.minute -1 3 , are commonly used. This is equivalent to only 0.3 IU.hour -1 . However, the oxytocin dose required to obtain adequate uterine tone is much larger for labouring women compared with those at elective caesarean section. This is explained by the down regulation of oxytocin receptors and desensitisation during labour 12, 13 . Therefore, in cases of prolonged labour and uterine atony, higher doses of oxytocin may not be effective and a different uterotonic drug should be considered early 20 .
Conclusion
The findings of these clinical trials indicate that it is time to review the recommendations for oxytocin administration after caesarean section -others have come to a similar conclusion 30 . To date the total number of women studied in clinical trials involving dose comparisons is small: 626 parturients in total. However, the available data suggests that slow, small boluses of oxytocin in combination with uterine massage are likely to be effective. At elective caesarean section, based on the ED 90 of 0.3 IU and the efficacy of 0.5 IU, a slow 0.3 to 1 IU bolus of oxytocin, followed by an infusion of 20 to 40 IU in one litre of isotonic solution over four hours, is suggested for women at low risk of postpartum haemorrhage. This 0.3 to 1 IU dose may be repeated once or twice before alternative uterotonic drugs are used. For the labouring parturient requiring caesarean delivery, a slow 3 IU bolus of oxytocin, also followed by an infusion, is suggested. If this proves insufficient, the 3 IU bolus may be repeated once, but further doses are unlikely to be efficacious because of receptor down-regulation and decreased responsiveness, so early consideration should be given to alternative uterotonic drugs. These dose regimens appear likely to be effective, while minimising the risk of haemodynamic compromise or maternal nausea.
As noted in many studies of oxytocin, additional uterotonic drugs are frequently required. Recommendations about bolus doses of oxytocin refer to initial doses only and ongoing assessment of their efficacy, in consultation with the obstetrician, is mandatory. A plan of management should be discussed with the obstetrician when dealing with parturients at high risk of uterine atony. The uterus should be massaged under direct vision at caesarean section by the obstetrician, who is in a position to assess uterine tone and request additional uterotonic drugs. In the recovery phase all women should be carefully monitored for postpartum haemorrhage.
The pregnant patient with congenital or acquired heart disease deserves particular care and consideration, as many of these women tolerate tachycardia or hypotension poorly, yet hypovolaemia due to postpartum haemorrhage must also be avoided. There is insufficient evidence to guide practice. It is comforting to know that uterine massage may often be adequate in achieving uterine contraction and that a small dose of oxytocin, given very slowly, is likely to contract the uterus. Nevertheless, severe haemodynamic disturbances may still occur 31 .
To summarise, for women at low risk of postpartum haemorrhage delivering by caesarean section, current evidence supports slow boluses of 0.3 to 1 IU at elective delivery and 3 IU at 'labouring' caesarean delivery, both followed by a 5 to 10 IU.h -1 oxytocin infusion, to decrease the risk of postpartum haemorrhage while minimising the adverse effects of oxytocin.
